Triumvira Doses First Patient with Novel T Cell Therapy in TACTIC-2 Clinical Trial

Triumvira, a clinical-stage company, is developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid and liquid tumors.